Holen Sie sich die Stockscreener-App
26.23
4.18%
-1.145
Handel nachbörslich:
26.39
0.16
+0.61%
Schlusskurs vom Vortag:
$27.38
Offen:
$27.22
24-Stunden-Volumen:
1.01M
Relative Volume:
0.76
Marktkapitalisierung:
$2.84B
Einnahmen:
$577.74M
Nettoeinkommen (Verlust:
$-149.78M
KGV:
-18.74
EPS:
-1.4
Netto-Cashflow:
$-78.21M
1W Leistung:
-9.58%
1M Leistung:
-21.49%
6M Leistung:
+45.88%
1J Leistung:
+95.89%
1-Tages-Spanne:
$26.15
$27.59
1-Wochen-Bereich:
$26.15
$29.29
52-Wochen-Spanne:
$11.70
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Firmenname
Novocure Ltd
Sektor
Branche
Telefon
44 (0)15 3475 6700
Adresse
NO. 4 THE FORUM, ST. HELIER
Vergleichen Sie NVCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
26.23 | 2.84B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
113.02 | 196.03B | 41.22B | 5.77B | 6.49B | 3.29 |
|
BSX
Boston Scientific Corp
|
95.65 | 140.97B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
362.80 | 138.31B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
85.25 | 109.31B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
71.04 | 41.90B | 6.60B | 4.16B | 490.10M | 6.93 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Eingeleitet | SVB Securities | Outperform |
| 2023-07-31 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Hochstufung | Wedbush | Underperform → Neutral |
| 2023-05-16 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Bestätigt | H.C. Wainwright | Buy |
| 2022-11-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-08 | Eingeleitet | Loop Capital | Buy |
| 2022-02-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2022-01-03 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-14 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-01-25 | Bestätigt | Piper Sandler | Overweight |
| 2020-09-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-09-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Herabstufung | Truist | Buy → Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Perform |
| 2020-05-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Hochstufung | SunTrust | Hold → Buy |
| 2019-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2018-11-02 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2018-04-18 | Bestätigt | Mizuho | Buy |
| 2018-02-23 | Bestätigt | Mizuho | Buy |
| 2017-05-24 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Bestätigt | Wedbush | Outperform |
| 2016-01-19 | Eingeleitet | Barclays | Underweight |
| 2015-12-02 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
NovoCure Ltd (NVCR) Shares Down 3.67% on Jan 14 - GuruFocus.com
NovoCure (NASDAQ:NVCR) Earns "Buy" Rating from HC Wainwright - MarketBeat
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings) - Benzinga
NovoCure’s (NVCR) Neutral Rating Reaffirmed at Wedbush - Defense World
NovoCure's (NVCR) Neutral Rating Reiterated at Wedbush - MarketBeat
Is Now The Time To Buy NovoCure Ltd (NASDAQ: NVCR) Stock? - Stocks Register
Novocure reports revenue growth, FDA approvals in 2024 - Investing.com India
Novocure Reports Strong 19% Revenue Growth, Hits $605M as Cancer Treatment Platform Expands - StockTitan
Investing in NovoCure (NASDAQ:NVCR) a year ago would have delivered you a 97% gain - Simply Wall St
NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Versant Capital Management Inc - Defense World
NovoCure Limited (NASDAQ:NVCR) Receives $32.67 Average PT from Brokerages - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Novocure CEO to Present at J.P. Morgan Healthcare Conference, Announces Investor Meetings - StockTitan
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Franklin Resources Inc. - MarketBeat
Geode Capital Management LLC Acquires 29,871 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure (NASDAQ:NVCR) Reaches New 12-Month HighShould You Buy? - MarketBeat
Research Analysts’ Recent Ratings Updates for NovoCure (NVCR) - Defense World
Tumor Treating Fields Market Growth in Future Scope 2024-2031 | Novocure GmbH and Zai Lab - openPR
Novocure's SWOT analysis: oncology med-tech firm's stock faces growth challenges By Investing.com - Investing.com South Africa
Novocure's SWOT analysis: oncology med-tech firm's stock faces growth challenges - Investing.com
NovoCure (NASDAQ:NVCR) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Novocure Stock Hits 52-Week High at $32.65 Amidst Strong Yearly Growth - Investing.com Australia
NovoCure (NASDAQ:NVCR) Shares Gap Up on Analyst Upgrade - MarketBeat
Novocure price target raised to $42 from $28 at Piper Sandler - Yahoo Finance
Novocure Stock Hits 52-Week High at $32.65 Amidst Strong Yearly Growth By Investing.com - Investing.com South Africa
NovoCure (NASDAQ:NVCR) Price Target Raised to $42.00 - MarketBeat
Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. - MSN
Brokerages Set NovoCure Limited (NASDAQ:NVCR) Target Price at $30.33 - MarketBeat
Quantinno Capital Management LP Cuts Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
47,034 Shares in NovoCure Limited (NASDAQ:NVCR) Bought by Weiss Asset Management LP - MarketBeat
NovoCure (NASDAQ:NVCR) Shares Gap UpHere's Why - MarketBeat
Holocene Advisors LP Purchases 22,276 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stake in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
MetLife Investment Management LLC Has $963,000 Holdings in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Why NovoCure Stock Was Winning Big This Week - Mitrade
BNP Paribas Financial Markets Has $2.75 Million Stock Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? - sharewise
CORRECTING and REPLACING – Novocure to Report Third Quarter 2016 Financial Results - Marketscreener.com
Edgestream Partners L.P. Takes Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Intech Investment Management LLC Makes New Investment in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
NovoCure Target of Unusually Large Options Trading (NASDAQ:NVCR) - Defense World
Novocure Stock Earns 96 RS Rating - Yahoo! Voices
NovoCure stock target increased on positive trial results By Investing.com - Investing.com Nigeria
NovoCure stock target increased on positive trial results - Investing.com
Novocure reports positive phase 3 results for tumor treating fields therapy - OutSourcing-Pharma.com
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals - Yahoo Finance
Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint - Yahoo Finance
NovoCure Limited (NASDAQ:NVCR) Looks Just Right With A 84% Price Jump - Simply Wall St
Novocure stock hits 52-week high at $28.26 amid robust growth - Investing.com Canada
Bridgewater Associates LP Sells 41,898 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Finanzdaten der Novocure Ltd-Aktie (NVCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.10%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):